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Genistein, a natural isoflavanoid phytoestrogen, is thought to be the active ingredient in soy that possesses breast cancer preventive
properties. The molecular mechanisms that are involved in its cancer preventive properties have not been completely understood. The
present study is designed to investigate the mechanism involved in the inhibitory action of genistein in MCF-7 cells. Genistein at 50 and
100 AM significantly arrested the growth of MCF-7 cells at G2/M phase (P< 0.05) and decreased at the proliferative S phase (P < 0.05).
Using cDNA microarray technology, genes differentially regulated by genistein were identified. In particular, as confirmed by reverse
transcriptase-polymerase chain reaction (RT-PCR), genistein up-regulated heat shock protein 105 (HSP) mRNA and down-regulated
mRNA expression of serum response factor (SRF), estrogen receptor (ER) a, disabled homolog 2 (DOC 2) and recombination activation
gene 1 (RAG-1). Using real time RT-PCR, we have shown that HSP and SRF mRNA were both regulated by genistein in a time- and
dose-dependent manner; however, it appears that only the effect of genistein on SRF mRNA, but not HSP mRNA expression, can be
partially abolished by cotreatment with estrogen antagonist ICI 182,780. Western blotting analysis showed that the expressions of the
ERa and SRF protein decreased significantly with genistein treatment (P < 0.05). These results suggest that the inhibitory action of
genistein on human breast cancer cells appears to be complex and is only partially mediated by the alteration of estrogen receptor-
dependent pathways.D 2003 Elsevier B.V. All rights reserved.Keywords: Genistein; cDNA microarray technology; Gene expression; MCF-7 cell
1. Introduction Despite the favorable association found between soyAsian women consuming a diet high in soy products
have a low incidence of breast cancer [1,2]. Isoflavone
phytoestrogens are the major active ingredients in soy
products such as tofu, soybean milk, miso and tempeh.
These phytoestrogens are found to be the normal constitu-
ents of human urine [3] and plasma [4,5] from subjects who
regularly consumed large amount of soy products. The
association between the lower risk of breast cancer and
the consumption of soy products has led to the widespread
interest in consumption of soy products, isoflavone supple-
ments and foods to which isoflavones have been added [6].0925-4439/03/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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bcmswong@polyu.edu.hk (M.-S. Wong).product intakes and risk of breast cancer in epidemiolog-
ical studies, conflicting data exist in experimental settings
using soy isoflavones for prevention of human breast
cancer [6–15]. Many factors have been shown to influ-
ence the properties of soy isoflavone on human breast
cancer cells in vitro and in vivo, including the circulating/
surrounding level of estrogen [7–9,12,16], presence or
absence of estrogen receptor as well as dosage [12,13,16–
18]. In the absence of endogenous estrogens, physiolog-
ical concentrations (1 nM to 10 AM) of genistein, a major
soy isoflavone, stimulate the growth of estrogen receptor
positive human breast cancer (MCF-7) cells [12,17,18] but
not estrogen receptor negative breast cancer (MDA-MB-
435) cells in vitro [12]; whereas high concentration of
genistein (>10 AM) inhibits the growth and survival of
both MCF-7 cells [12,17] and MDA-MB-435 cells
[19,20].
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isoflavone, genistein, in human breast cancer is vital for
understanding its properties in vitro and in vivo and is
therefore an area that is under intense investigation. Genis-
tein can bind to estrogen receptors, affects estrogen-regulat-
ed gene expression [21] and displays both estrogen agonist
[12] and antagonist properties [16]. It can also exert its
effects in many ways without direct interaction with the
estrogen receptors. It was previously shown to alter estrogen
metabolism via its inhibitory action on aromatase [22]. It is
also a well-known protein tyrosine kinase inhibitor that
competes with ATP for binding to tyrosine kinase, and
thereby interferes with tyrosine kinase cascade activated by
mitogens [9,23]. In addition, genistein has been demonstrat-
ed to inhibit DNA topoisomerase activity [24], suppress
angiogenesis [25] and induce apoptosis [26,27] and stress
[28].
The present study is designed to investigate the molecular
mechanism involved in the inhibitory action of genistein in
estrogen receptor positive human breast cancer (MCF-7)
cells. Using cDNA microarray technology, differentially
regulated genes in response to high concentrations of genis-
tein treatment were identified. The regulations of heat shock
protein (HSP) and serum response factor (SRF) mRNA, two
of the newly identified genistein-regulated genes, were
studied using real time reverse transcriptase-polymerase
chain reaction (RT-PCR). It is hoped that this study will
provide new insights for understanding the inhibitory action
of genistein in human breast cancer and that the newly
identified targets can serve as potential targets for cancer
drug development.2. Materials and methods
2.1. Culture of human breast cancer cell line (MCF-7)
MCF-7 cells (ATCC no. HTB-22) were routinely cul-
tured in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 5% fetal bovine serum (FBS), penicil-
lin 100 IU/ml and streptomycin 100 Ag/ml. At 50% to
60% confluence, cells were transferred to phenol-red-free
DMEM supplemented with 5% charcoal-stripped fetal
bovine serum (sFBS), penicillin 100 unit/ml and strepto-
mycin 100 Ag/ml for 4 days before the cells were treated
with genistein (50 AM, 100 AM) (Sigma, St. Louis, MO,
USA) for 24 h. Cells were cultured at 37 jC in a hu-
midified atmosphere of 95% air and 5% CO2. For study
of the regulation of SRF and HSP expression, MCF-7
cells were subjected to treatment with 100 AM genistein
for different time periods (6, 24, 48 h) or different
concentrations (1, 50 or 100 AM) of genistein for 24 h.
For ICI 182,780 (Tocris, Bristol, UK) treatment, MCF-7
cells were exposed to 100 AM genistein in the presence
or absence of estrogen antagonist ICI 182,780 (1 AM) for
24 h.2.2. Flow cytometry
After treatment, MCF-7 cells were isolated into conical
tubes, washed twice with phosphate-buffered saline (PBS)
and fixed in 70% ice-cold ethanol at  20 jC. For DNA
analysis, cells were centrifuged and washed two times with
PBS. DNA contents of the nuclei were determined by stain-
ing nuclear DNA with propidium iodide (PI, Sigma, 50 Ag/
ml) solution containing 50 Ag/ml of RNase A and incubated
at 37 jC in the dark for 30min. The DNA content, as reflected
by the fluorescence signal of PI, was measured by using Flow
Cytometer (Becton-Dickinson, Immunocytometry Systems,
Mountview, CA). Distribution of cells in different phases of
cell cycle was determined using a software program Modfit
(Becton-Dickinson, Immunocytometry Systems) [29].
2.3. Fluorescent cDNA microarray analysis of MCF-7 cells
The human cDNA probes generated from Unigene sets
were printed onto polylysine-coated slides by microarrayer
(SPBIO, Hitachi Software Engineering) in a lower density
format. The cDNA probes printed on the microarray slides
were immobilized to the slides by 60 mJ of UV light cross-
linking. The cDNA chip consists of 448 human genes, which
encode for stress response, oncogene, kinase and phospha-
tase, G-protein, apoptosis, cell cycle, tumor suppressor,
transcription factor, growth factor and receptor. The control
genes including housekeeping genes are printed in duplicate.
Fifty micrograms of total RNA was used as template to
prepare cDNA probes labeled with Cy5-dUTP or Cy3-dUTP
(Amersham Pharmacia Biotech, Piscataway, USA) by using
SuperScript II RT kit (Roche Applied Science, Mannheim,
Germany). Hybridization was carried out at 65 jC for 16
h and signal was obtained by a ScanArrayR 4000 (Gsi
Lumonic, USA). Clustering analysis was carried out by using
Cluster software from Elsein’ lab (Stanford University, Cal-
ifornia, USA) and a modified SOM method developed in-
house. A differentially expressed gene is defined by a ratio of
treated/control >2.0 or < 0.5.
2.4. Verification of cDNA microarray data using RT-PCR
analysis
Total RNAwas isolated from cells by using Trizol reagent
according to the standard protocol. Total RNA (2 Ag) was
used to generate cDNA in each sample using the SuperScript
II reverse transcriptase with oligo(dT) 12–18 primers. Ali-
quots (5–10%) of total cDNA were amplified in each PCR
reaction mixture that contains 0.5 AM of sense and antisense
primers (Genemed Synthesis, Inc., South San Francisco,
USA) of selected genes (Table 1). PCR amplification was
performed on a GeneAmp 9600 PCR system (Perkin Elmer,
Foster City, CA, USA). The PCR products were analyzed on
agarose gel electrophoresis. Optical densities of ethidium
bromide-stained DNA bands were quantified by Luminal
Imager (Roche Molecular Biochemicals) and the mRNA
ysica Acta 1638 (2003) 187–196
Table 1
Primers used for RT-PCR verification
Primer Sequence Product
Orientation Size (bp) Annealing temperature (jC)
HSP AGGAGTTCCATATCCAGAA sense 306 46
CAGCTCAACATTCACCAC antisense
ERa AAGTTCAGGCACAATTGGATG sense 502 50
CCCTGCATGACACTGATTACA antisense
SRF ACTGCCTTCAGTAGGAACAA sense 595 56
TTCAAGCACACACACTCACT antisense
RAG-1 GTCAGTGAGGTCAAAAGGAG sense 597 53
ACAGGTCCCCTGAATCAA antisense
DOC2 GGGATCGCCTGGTGTCACCAA sense 300 57
TTGTCCCTGAGACCGACCA antisense
GAPDH ACCACAGTCCATGCCTACAC sense 452 55
TTCACCACCCTGTTGCTGTA antisense
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housekeeping gene, glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH).
2.5. Real-time quantitative RT-PCR
PCR amplification and analysis were achieved using a
LightCycler instrument and software version 3.5, respective-
ly (Roche Applied Science). Thermocycling were done in a
final volume of 15 Al containing 1 Al cDNA sample or
calibrator; 4 mM MgCl2; 0.5 AM of each primers; 1.5
Al LightCycler FastStart DNA Master SYBR Green 1 mix
(Roche Applied Science). After denaturing of cDNA at 95 jC
for 10 min, the cycling conditions were as follows: 45 cycles
consisting of denaturation at 95 jC for 10 s, annealing at 55
jC (for SRF), 46 jC (for HSP) or 56 jC (for GAPDH) for 10
s, and extension at 72 jC for 18 s. Following the completion
of the PCR amplification reaction, a melting curve analysis
was performed by heating the sample to 95 jC programmedFig. 1. Effect of genistein on cell cycle distribution in human breast cancer
(MCF-7) cells. MCF-7 cells were cultured and treated with different
concentrations of genistein or its vehicle for 24 h. Flow cytometric analysis
of cell cycle distribution in MCF-7 cells was performed (see Materials and
methods). Distribution of cells in different phases of cell cycle was
determined using a software program Modfit (Becton-Dickinson, Immu-
nocytometry Systems). Results were obtained from three independent
experiments and expressed as meanF S.E. *P < 0.05 vs. control, n= 3.for 0 s followed by cooling down to 60 jC for 15 s and slowly
heating the samples at 0.1 jC/s to 95 jC while the fluores-
cence was measured continuously. GAPDH was used as a
reference gene for internal control. The fluorescence signal
was plotted in real time against the temperature to produce
melting curves of each sample. Melting curves were then
converted tomelting peaks by plotting the negative derivative
of the fluorescence with respect to temperature against
temperature ( dF/dT versus T). Thus, each specific PCR
product generates a specific signal and therefore a product-
specific melting peak. After completion of LightCycler
analysis, PCR products were subjected to electrophoresis
on a 1% agarose gel, stained with ethidium bromide, visual-
ized and photographed under ultraviolet illumination. Ex-
pected band lengths were 595 bp for SRF, 306 bp for HSP and
452 bp for GAPDH. A relative standard curve of target and
reference gene for quantification of RT-PCR product wasFig. 2. Representative image of cDNA microarray showing the effect of
genistein on gene expression profile in human breast cancer (MCF-7) cells.
Total RNA from control samples and from genistein-treated samples were
used to prepare Cy3- and Cy5-labeled cDNA, respectively. The probes were
hybridized to the microarray as described in Materials and methods. In this
representative image, up-regulated genes in response genistein in MCF-7
are shown as red spots while the down-regulated genes are shown as green
spots. The two differentially regulated genes in MCF-7 cells treated with
100 AM of genistein, HSP and RFC4 are indicated by arrow.
Table 2
List of differentially expressed genes in MCF-7 cells treated with different
concentrations (50 and 100 AM) of genistein
Accession no. Gene name Fold Function
G50 G100
Up-regulated genes
AB003334 heat shock protein
105 kD (HSP)
2.67 2.45 stress response
Y15801 protein kinase,
Y-linked (PRKY)
2.24 1.96 transcription
K02581 thymidine kinase 1,
soluble (TK1)
1.50 2.00 salvage-pathway
enzyme for dTTP
formation
Down-regulated genes
X03635 ER a (ER) 0.49 0.39 transcription
J03161 serum response
factor (SRF)
0.49 0.59 transcription
factor
M29474 recombination activating
gene 1 (RAG-1)
0.52 0.38 V(D)J
recombination
X51602 fms-related
tyrosine kinase 1
(VEGFR-1)
0.50 0.43 endothelial cell
proliferation and
angiogenesis
U39050 disabled
(Drosophila)
homolog 2 (DOC2)
0.49 0.57 signal
transduction
AA600213 replication factor
C(activator 1)4 (RFC4)
0.43 0.57 elongation DNA
template
M57627 interleukin 10 (IL10) 1.07 0.43 apoptosis
X76104 thymidine kinase
2,mitochondria (TK2)
0.83 0.44 mitochondria
DNA synthesis
MCF-7 cells were cultured and treated with 50 AM (G50) and 100 AM
(G100) of genistein or its vehicle for 24 h as described in Materials and
methods. Total RNA were extracted and labeled for cDNA microarray
experiments. Results are expressed as fold change as compared to samples
extracted from vehicle-treated cells and are the average of two independent
microarray experiments.
Fig. 3. RT-PCR analysis of differentially regulated genes in MCF-7 cells in
response to treatment with genistein. MCF-7 cells were treated with 50 AM
(G50) and 100 AM (G100) genistein or its vehicle (C) for 24 h. Total RNA
was isolated and subjected to semi-quantitative RT-PCR analysis. Primers
for RT-PCR analysis were listed in Table 1. GAPDH was used as a control.
A representative of two experiments is shown.
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untreated control sample was used as a calibrator. The
Relative Quantification Software was used to create a relative
standard curve and stored as a coefficient (*.cof) file that can
be used for each analysis. In this quantification method, the
result is expressed as the target/reference ratio of each sample
divided by the target/reference ratio of the calibrator.
2.6. Western blot analysis
Proteins were obtained by cell lysis in Nonidet P-40 buffer
(20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM CaCl2, 1
mMMgCl2, 10% glycerol, 1%Nonidet P-40). The buffer was
supplemented with protease inhibitors (2 Ag/ml aprotinin, 2
Ag/ml leupeptin, 1 mM PMSF) and phosphatase inhibitors (1
mM sodium orthovanadate, 10 mM NaF). All of these
chemicals were from Sigma. Protein concentrations were
analyzed by the method of Bradford (Bio-Rad Laboratory,
USA) [30]. Equal amounts of cytosolic proteins (20 Ag) were
separated by SDS-PAGE on 10% reducing gels, and trans-
blotted to PVDF membranes (Immobilon-P, Millipore Corp.,
MA, USA). The membrane was treated with primary anti-bodies (Sigma and Santa Cruz Biotechnology, Inc., Santa
Cruz, CA) followed by incubation with appropriate horse-
radish peroxidase-conjugated secondary antibodies (Santa
Cruz Biotechnology). The antigen–antibody complexes
were detected using an enhanced chemiluminescence (ECL,
Pierce, Rockford, IL, USA) reagent [31] and visualized by the
Lumi-Imager with the software Lumi Analyst version 3.10
(Roche, Mannheim, Germany).
2.7. Statistical analysis
Results are expressed as meansF standard error of mean
(S.E.). The significance of differences between group means
was determined by one-way ANOVA. P value < 0.05 was
considered statistically significant.
3. Results
3.1. Effects of genistein on cell cycle kinetics
The effects of genistein on cell cycle in MCF-7 cells
were determined using flow cytometry. Representative
graphs are shown in Fig. 1. When MCF-7 cells were treated
with high concentration of genistein (50 AM and 100 AM),
the proportion of cells in G2/M phase increased (P < 0.05)
and the proportion of cells in S phase decreased (P < 0.05).
These results confirmed the studies reported by others
[9,26] that high concentration of genistein produced cyto-
Fig. 5. Quantitative RT-PCR analysis of serum response factor (SRF)
mRNA in MCF-7 cells. (A) Time course of SRF mRNA expression in
MCF-7 cells in response to with 100 AM genistein. MCF-cells were
cultured with 100 AM genistein for 0, 6, 24, 48 h and total RNA was
isolated and subjected to quantitative RT-PCR analysis. *P < 0.01 vs.
control, n= 3. (B) Dose response of SRF mRNA expression in MCF-7 cells
treated with different concentrations of genistein. MCF-7 cells were
cultured and treated with 1 AM (G1), 50 AM (G50) and 100 AM (G100)
genistein or its vehicle (C) for 24 h and total RNA was isolated and
subjected to quantitative RT-PCR analysis. *P< 0.05 vs. control, n= 3.
Fig. 4. Quantitative RT-PCR analysis of heat shock protein105 kD (HSP)
mRNA in MCF-7 cells. (A) Time course of HSP mRNA expression in
MCF-7 cells in response to 100 AM genistein. MCF-cells were cultured
with 100 AM genistein for 0, 6, 24, 48 h and total RNA was isolated and
subjected to quantitative RT-PCR analysis. *P< 0.05 vs. control, n= 3. (B)
Dose response of HSP mRNA expression in MCF-7 cells treated with
different concentrations of genistein. MCF-7 cells were cultured and treated
with 1 AM (G1), 50 AM (G50) and 100 AM (G100) genistein or its vehicle
(C) for 24 h and total RNA was isolated and subjected to quantitative RT-
PCR analysis. *P < 0.05 vs. control, n= 3.
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and arresting cells at critical checkpoint. In this study we
were interested in investigating how genistein inhibits cell
growth at high concentration.
3.2. Gene expression pattern of MCF-7 cells treated with
genistein
The inhibitory effect of genistein could be mediated
through the modulation of gene expression in human
breast cancer cells. The gene expression profiles of
MCF-7 cells in response to different concentrations (50
and 100 AM) of genistein were obtained by using a cDNA
microarray containing 448 human genes (Fig. 2). Lists of
up-regulated and down-regulated genes in MCF-7 cells
treated with different doses of genistein are shown in
Table 2. At 50 and 100 AM of genistein, the expressions
of HSP 105 kD, protein kinase (Y-linked, PRKY) and
thymidine kinase 1 (TK1) were persistently up-regulated;
while the expression of SRF, ERa, disabled (Drosophila)
homolog 2 (DOC 2), recombination activating gene 1
(RAG-1), replication factor C (RFC4) and fms-related
tyrosine kinase 1 (VEGFR-1) were down-regulated. Ourresults also indicated that interleukin 10 (IL10) and thy-
midine kinase 2 (TK2) were down-regulated only by 100
AM genistein.
3.3. Verification of expression of selected genes and real-
time quantitative PCR of HSP mRNA and SRF mRNA
expression
Among the up-regulated genes, we selected HSP for
RT-PCR verification. From the list of down-regulated
genes, SRF, ERa, DOC 2 and recombination activation
gene 1 (RAG-1) were selected. The RT-PCR results, as
shown in Fig. 3, demonstrated identical expression pattern
for all selected genes as revealed by microarray analysis.
To further characterize the effect of genistein on HSP and
SRF mRNA expression, time-course and dose-response
experiments were performed. Using quantitative RT-PCR,
genistein was shown to significantly enhance HSP mRNA
expression as early as 6 h after treatment (P < 0.05), and
the up-regulation persisted for up to 48 h (P < 0.05) (Fig.
4A). Moreover, treatment with different concentrations of
genistein resulted in a dose-dependent increase in the level
Fig. 7. Western blot analysis of the expression of ERa in MCF-7 cells
treated with different concentrations of genistein. MCF-7 cells were
cultured and treated with 1 AM (G1), 50 AM (G50) and 100 AM (G100)
genistein or its vehicle (C) for 24 h. Cells were lysed and proteins were
fractionated using 10% SDS-PAGE and immunoblotted with antibody
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Fig. 4B. In contrast, SRF mRNA expression was down-
regulated by genistein in a time-dependent manner. The
down-regulation persisted throughout the duration of treat-
ment with genistein (P < 0.01) (Fig. 5A). In addition,
genistein treatment results in a dose-dependent decrease
in the mRNA expression of SRF (50 and 100 AM,
P < 0.01) (Fig. 5B).
Since previous studies showed that genistein could
behave either as an estrogen agonist or estrogen antagonist
[32], experiment was designed to determine if the regula-
tions of HSP and SRF mRNA by genistein were mediated
through estrogen receptor using an estrogen antagonist, ICI
182,780. The result showed that the up-regulation of HSP
mRNA by genistein persisted in the presence of ICI
182,780 (Fig. 6A), suggesting the regulation of HSP by
genistein is not mediated through ER-dependent pathway.
On the other hand, the down-regulation of SRF was
partially abolished by cotreatment with ICI 182,780 (Fig.
6B), indicating that ER pathway was at least in partFig. 6. Effect of estrogen antagonist ICI 182, 780 on the regulation of HSP
and SRF mRNA expressions by 100 AM of genistein. (A) MCF-7 cells
were cultured and treated with 100 AM genistein in the presence and
absence of 1 AM ICI 182, 780 for 24 h as described in Materials and
methods. Total RNA was isolated and subjected to quantitative RT-PCR
analysis for HSP mRNA. *P < 0.05 vs. control, n= 3. (B) MCF-7 cells were
cultured and treated with 100 AM genistein in the presence and absence of 1
AM ICI 182, 780 for 24 h as described in Materials and methods. Total
RNA was isolated and subjected to quantitative RT-PCR analysis for SRF
mRNA. a and b are significantly different from control ( P < 0.05). a and b
are different ( P< 0.05).
against ERa as described in Materials and methods. The immunoblot is a
representative of three independent experiments. Results were obtained
from three independent experiments and expressed as meanF S.E.
*P< 0.05 vs. control, n= 3.involved in the inhibitory effect of genistein on SRF mRNA
expression.
3.4. Effects of genistein on ER and SRF protein expressions
Previous studies demonstrated that genistein serves as an
antiestrogen by interfering with the tumor promoting effectFig. 8. Western blot analysis of the expression of SRF in MCF-7 cells
treated with different concentrations of genistein. MCF-7 cells were
cultured and treated with 1 AM (G1), 50 AM (G50) and 100 AM (G100)
genistein or its vehicle (C) for 24 h. Cells were lysed and proteins were
fractionated using 10% SDS-PAGE and immunoblotted with antibody
against SRF as described in Materials and methods. The immunoblot is a
representative of three independent experiments. Results were obtained
from three independent experiments and expressed as meanF S.E.
*P< 0.05 vs. control, n= 3.
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demonstrated that genistein down-regulated ERa mRNA
expression (Table 2 and Fig. 3). To determine if genistein
also down-regulate ERa protein expression, Western blot-
ting analysis of MCF-7 cells treated with different concen-
tration of genistein was performed. As shown in Fig. 7, ERa
protein expression in MCF-7 cells decreased significantly
with increasing genistein concentrations (at 50 and 100 AM,
P < 0.05). Thus, our results indicated that the inhibitory
action of genistein on MCF-7 cells involved the down-
regulation of ERa at both the mRNA and protein level.
Similar to ER that serves a pivotal role in mediating the
proliferative action of estrogen in MCF-7 cells, SRF is an
important transcription factor that mediates the proliferative
actions of both estrogen and mitogens via its involvement in
transcriptional regulation of c-fos, a protooncogene [33,34].
As genistein appears to down-regulate SRF mRNA in dose-
dependent manner, we therefore determined if the down-
regulation of SRF mRNA by genistein results in a parallel
decrease in SRF protein expression in MCF-7 cells. Western
blotting analysis showed that SRF protein levels were also
reduced by genistein in a dose-dependent manner (P < 0.05)
(Fig. 8), indicating that genistein at high concentration
inhibited SRF expression transcriptionally and post-tran-
scriptionally.4. Discussion
Genistein, an active ingredient in soy products,
behaves differently at different concentrations in human
breast cancer MCF-7 cells. Using cDNA microarray
technology, several targets or pathways that might be
affected by high concentration of genistein were identi-
fied. Genes that are up-regulated by high concentration of
genistein include genes that are involved in cell salvage
response, while genes that are down-regulated include
those that participate in different signaling pathways that
lead to cell growth and differentiation.
The up-regulated genes in MCF7 cells in response to
high concentration of genistein treatment are genes associ-
ated with stress response (HSP 105,), transcription (protein
kinase, Y-linked, PRKY) and salvage-pathway enzyme for
dTTP formation (TK1), indicating the activation of cellular
salvage response in MCF-7 cells upon genistein treatment.
Previous reports have shown that stress pathway is involved
in the anti-proliferative effects of genistein [28]. HSPs,
which function mainly as molecular chaperones, allow cells
to adapt to gradual changes in their environment and to
survive in otherwise lethal conditions. The events of cell
stress and cell death are closely linked and HSP induction in
response to stress appears to function at key regulatory
points in the control of apoptosis. A recent study [35]
demonstrated that overexpression of Hsp 105a can enhance
stress-induced apoptosis in mouse embryonal F9 cells.
Therefore, the up-regulation of HSP by genistein in MCF-7 cells provides direct evidence for the activation of stress
pathways and possibly an enhancement of the process of
apoptosis. In addition, our results indicate that genistein up-
regulation of HSP in MCF-7 cells is independent of the
estrogen receptor-mediated pathways as estrogen antagonist
ICI 182,780 fails to abolish the action of genistein.
The down-regulated genes in genistein-treated MCF-7
cells are participating in different signaling pathways in-
volved in growth and differentiation. Three of the down-
regulated genes are involved in pathways that mediate mito-
genic responses:
1. SRF is a transcription factor that binds to serum response
element at the site of transcription initiation of many
growth response-related genes such as c-fos. Both E2 and
IGF-I were previously shown to activate MCF-7 cell
proliferation via the activation of SRF response element
[33].
2. Disabled (Drosophila) homolog 2 (DOC 2), another
down-regulated gene that is known to be the human
homologous of the murine mitogen responsive phospho-
protein p96, is a cellular signal transduction component of
the colony-stimulatory factor 1 (csf-1)-dependent signal-
ing pathways. Csf-1 binds to c-fms protooncogene,
triggers receptor dimerization and activates downstream
signaling molecules, including DOC-2 [36].
3. Fms-related tyroinse kinase 1 (flt-1), also known as
vEGFR-1, is a tyrosine-protein kinase receptor. Vascular
endothelial growth factor (vEGF) and v-EGFR (flt-1) were
previously showed to play important roles in stimulating
vascular cell proliferation, invasion and angiogenesis in
endothelial cells [37].
We have specifically studied the time-response and
dose-response of SRF mRNA expression in MCF-7 cells
treated with 100 AM of genistein using quantitative RT-
PCR. The result indicated that genistein decreased SRF
protein and mRNA expression in a dose-dependent man-
ner. Since SRF is an important transcription factor that
mediates the action of growth factors and the non-ge-
nomic actions of estrogen [33,34], our results suggest that
the inhibitory effect of genistein might involve the sup-
pression of both the ER- and IGFR-mediated pathway via
the down-regulation of SRF expression in MCF-7 cells.
In addition, our results also suggest that the inhibitory
action on SRF mRNA is not solely mediated by estrogen
receptor-dependent pathways as its action on SRF expres-
sion cannot be completely abolished by cotreatment with
ICI 182,780. The down-regulation of DOC-2 and vEGFR
in MCF-7 cells upon genistein treatment suggests that
both csf-1- and vEGFR-dependent pathways might be
partially responsible for the inhibitory action of genistein
in human breast cancer cells. It is of interest to note that
a recent study by Li and Sarkar [38], which employed a
cDNA microarray containing 12558 genes to characterize
differential gene expression in response to genistein
Fig. 9. Summary of current understanding of inhibitory effect of genistein in MCF-7 cells. Functions with reference number represent known mechanism and
bold words without reference number represent new mechanism revealed by our cDNA microarray technology. # represents inhibition, z represents
stimulation.
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that genistein could down-regulate vEGF gene expression.
Together, these data support that angiogenesis-related
genes, such as VEGF and vEGFR, are major targets of
genistein in cancer cells.
Our results also indicated that genistein at high con-
centration can directly suppress ER-dependent pathways.
It is well known that genistein has weak binding affinity
toward ER [10] and was previously demonstrated to
interfere with the binding of estrogen to estrogen receptor
[32]. The present study further showed that genistein
could inhibit ERa mRNA and protein expression in
human breast cancer cell line in a dose-dependent manner.
As estrogen is a major stimulator for the growth of many
breast tumors, the inhibition of its receptor by genistein
will provide a direct means of decreasing its responsive-
ness to circulating or surrounding estrogen, thereby lim-
iting estrogen-dependent cell growth.
Other down-regulated genes in response to treatment
with high concentration of genistein are involved in differ-
ent cellular activities, including DNA replication (Replica-
tion factor C 4, RFC4), V(D)J recombination of immuno-
globulin and T cell receptor genes (recombination activating
gene 1, RAG-1) [39], apoptosis (IL10) [40] and mitochon-
dria DNA synthesis (TK2) [41]. The down-regulation of
RFC4, and hence DNA replication, by genistein provides a
possible mechanism for the decrease in the S-phase of cellcycle in MCF-7 upon treatment with high concentration of
genistein (Fig. 2). However, the exact role of each of these
down-regulated genes in mediating the inhibitory action of
genistein remains to be determined.
In conclusion, the present study suggests that high
concentration of genistein induces stress response, inter-
feres with ER action by down-regulation of ER both at the
transcriptional and post-transcriptional level, inhibits the
responses of MCF-7 cells to growth factor by decreasing
tyrosine kinase activities of growth factor receptors as well
as the expression of its downstream responsive transcrip-
tion factor such as SRF, decreases DNA replication, and
induces apoptosis. Summary of the current understanding
of the inhibitory action of genistein in MCF-7 cells is
shown in Fig. 9. Further investigation is needed to verify
the possible roles of these differentially regulated genes in
the susceptibility of human breast cancer (MCF-7) cell line
to the action of genistein.Acknowledgements
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